E-Device ( DrugBank: - )

3 diseases

46. 悪性関節リウマチ

臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03357471 (ClinicalTrials.gov)	November 3, 2017	23/11/2017	Study to Test the Safe and Effective Use of an e-Devicefor the Self-injection of Certolizumab Pegol ...	A Multicenter, Open-Label Study to Evaluate the Safe and Effective Use of an Electro-Mechanical Inje ...	Moderate and Severe Active Rheumatoid Arthritis;Active Psoriatic Arthritis;Active Ankylosing Spondyl ...	Drug: e-Device	UCB Biopharma S.P.R.L.	NULL	Completed	18 Years	N/A	All	70	Phase 3	United States

臨床試験数 : 2,442 / 薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03357471 (ClinicalTrials.gov)	November 3, 2017	23/11/2017	Study to Test the Safe and Effective Use of an e-Devicefor the Self-injection of Certolizumab Pegol ...	A Multicenter, Open-Label Study to Evaluate the Safe and Effective Use of an Electro-Mechanical Inje ...	Moderate and Severe Active Rheumatoid Arthritis;Active Psoriatic Arthritis;Active Ankylosing Spondyl ...	Drug: e-Device	UCB Biopharma S.P.R.L.	NULL	Completed	18 Years	N/A	All	70	Phase 3	United States

臨床試験数 : 574 / 薬物数 : 359 - (DrugBank : 68) / 標的遺伝子数 : 41 - 標的パスウェイ数 : 146

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03357471 (ClinicalTrials.gov)	November 3, 2017	23/11/2017	Study to Test the Safe and Effective Use of an e-Devicefor the Self-injection of Certolizumab Pegol ...	A Multicenter, Open-Label Study to Evaluate the Safe and Effective Use of an Electro-Mechanical Inje ...	Moderate and Severe Active Rheumatoid Arthritis;Active Psoriatic Arthritis;Active Ankylosing Spondyl ...	Drug: e-Device	UCB Biopharma S.P.R.L.	NULL	Completed	18 Years	N/A	All	70	Phase 3	United States